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Clinical Comparison between
in treating a variety of carcinomas including refractory ovarian cancer, gastric cancer and non-small-cell lung cancer (NSCLC) (Drummond et al., 1999) , but one problem associated with the administration of paclitaxel is its low solubility in most pharmaceutically-acceptable solvents. The paclitaxel formulation used clinically contains polyethoxylated castor oil (Cremophor EL) and dehydrated ethanol in a 1:1 (vol:vol) ratio. Cremophor EL is reported to cause toxic effects, e.g., life-threatening anaphylaxis (Szebeni et al., 1998; Van Zuylen et al., 2001 ). The administration of antihistamines and glucocorticoids is necessary to manage these adverse effects (Bookman et al., 1997) , but these co-administered drugs have raised the possibility of additional pharmacokinetic and pharmacodynamic interactions with paclitaxel. This problem is sought to be alleviated either by synthesizing more soluble derivatives or by the administration of paclitaxel bound to more soluble formulation vehicles (Kobayashi et al., 2006) . A variety of drug-delivery approaches were investigated to eliminate vehicle toxicity from paclitaxel formulations (Sharma et al., 1996; Scialli et al., 1997) . Sharma and Straubinger developed a liposomebased paclitaxel formulation (Sharma et al., 1994) . It provides a formulation alternative for the administration (Chen et al., 2003; Yang et al., 2006; Kong et al., 2007) . Yang et al. (2006) reported the cytotoxic effects and antitumor activities of Lipusu and concluded that Lipusu possesses the same antitumor activities in vitro and in vivo but its toxicity is lower than that of paclitaxel injection under the same dosage. Kong et al. (2007) suggested that the response rate (RR) is 39.1% in the treatment of NSCLC patients with Lipusu and cisplatin. Chen et al. (2003) compared Lipusu with conventional paclitaxel on treatments of breast cancer and NSCLC and demonstrated that both of them have similar efficacy but the former reduces the incidence of serious hypersensitive reactions significantly more than the latter. However, it is not clear whether the efficacy of paclitaxel liposome is superior to conventional paclitaxel. We hypothesize that paclitaxel liposome could be superior to conventional paclitaxel in treating patients with advanced gastric cancer.
Materials and Methods
Patient
All the patients were required to be pathologically diagnosed with gastric cancer, with Karnofsky performance status ≥ 60, aged between 18 and 75 years, predicted survival time ≥ 3 months. With adequate bone marrow (white blood cell count > 4.0×10 9 and platelet count > 100×10 9 ), and liver function (bilirubin and transaminases < 2 times the upper limit normal), no heart and kidney disease, and signed an informed consent before chemotherapy. Patients excluded from this study if they failed to complete two cycles of chemotherapy, with any serious medical or psychiatric condition, or other malignancies. Pregnant or lactating women are excluded from the study.
Treatment method
Eligible patients were divided into paclitaxel liposome group (Group A) or paclitaxel group (Group B). 
Response Evaluation
Response evaluation with RECIST tumor chemotherapy criterion requirements was divided into complete remission (CR), partial response (PR), stability (SD), and disease progression (PD). It is defined that response rate (RR) = (CR + PR)/total, and clinical control (DCR) = (CR + PR + SD) /total (Van Zuylen et al., 2001 ). According to the WHO acute and subacute toxicity of anticancer drugs to identify performance and classification standard, adverse reaction is divided into 0 -Ⅳ degrees.
Statistical analysis
SPSS13.0 statistical software was used for statistical analysis. Statistically significant difference was set at P < 0.05. We have enough experience in conducting medical researches, and have published some results elsewhere (Huang et al., 2004; Zhou et al., 2009; Jiang et al., 2010; Yan et al., 2010; Gao et al., 2011; Yan et al., 2011; Zhang et al., 2011; Gong et al., 2012; Li et al., 2012; Yu et al., 2012) .
Results
Sixty-two patients meet the study criteria and entered two study groups. General characteristics of patients are shown in Table 1 .
Efficacy Observation
There are 32 patients in group A and 30 in group B. However each group has 2 patients who cannot complete at least 2 cycles of chemotherapy and dropped out. Other cases are eligible for evaluating RR, which was conducted DOI:http://dx.doi.org/10.7314/APJCP.2013 .14.4.2591 Leukocytopenia  8  4  2  1  54  8  5  2  0  50  Thrombocytopenia  3  2  0  0  18  4  1  0  0  17  Hemoglobin reduction  4  3  1  0  29  3  4  1  0  27  Nausea and vomiting  8  4  2  0  50  4  2  1  0  23  Rash  7  0  0  0  25  1  0  0  0  3  Baldness  9  2  1  0  43  8  2  1  0  37  Dyspnoea  4  1  0  0  18  0  0  0  0  0  Myalgia  15  3  1  0  68  3  0  0  0  10  Liver dysfunction  3  1  0  0 after 4 cycles of chemotherapy. RR of group A and B were 47% and 46% respectively. No significant difference in RR was detected in two groups (P > 0.05), as shown in Table 2 .
Toxicity Assessment
In 2 groups, main adverse reactions are hematologic and gastrointestinal, and nervous system toxicities (P > 0.05). The difference of incidence in alopecia, diarrhea and constipation between two groups is not statistically significant (P > 0.05), but the incidence of nausea and vomiting, rash, shortness of breath, muscle pain and peripheral neuritis in group A is lower than those in group B, with statistically significant difference (P < 0.05) ( Table  3) .
Discussion
Paclitaxel is a broad-spectrum plant kind of anticancer drugs. Through combination with cellular microtubules beta, it is reported to promote the microtubule polymerization, suppress the depolymerization and block mitosis, and further to inhibit tumor growth (Szebeni et al., 1998) . In recent years, clinical studies suggested that paclitaxel has significant curative effect for a variety of solid tumors. But ordinary paclitaxel is almost insoluble in water, paclitaxel formulation used clinically contains Cremophor EL. Cremophor EL is associated with toxic effects, e.g., life-threatening anaphylaxis (Szebeni et al., 1998; Van Zuylen et al., 2001) . Premedication with antihistamines and glucocorticoids is necessary (Bookman et al., 1997) . Study in recent years suggested that, liposomes as a drug carrier could improve the histocompatibility and cellular affinity, improve the stability of paclitaxel, and reduce toxicity (Kobayashi et al., 2006) . This study suggested that the RR of paclitaxel liposome combined with tegafur and oxaliplatin be slightly superior to conventional paclitaxel in treating patients with advanced gastric cancer. The incidence of allergy, nausea and vomiting, rash, muscle pain in paclitaxel liposome group was lower than that in conventional paclitaxel group. In this study, RR of paclitaxel liposome and conventional paclitaxel was 47% and 46%. No statistically significant difference was detected between two groups, and this result is consistent with previous studies (Sharma et al., 1994; Sharma et al., 1996; Scialli et al., 1997) . Before paclitaxel, patients should take premedication. But patients do not need strong premedication before paclitaxel liposome. Thus the latter is proper for patients who can not tolerate heavy dose of hormone.
In conclusion, paclitaxel liposome is as effective as conventional paclitaxel when combined with tegafur and oxaliplation in treating patients with advanced gastric cancer, and adverse reactions of paclitaxel liposome are less common.
